Senior Vice President – Regulatory Affairs & Quality

• Dr. Fischer has 20+ years of experience in regulatory affairs and clinical development
• From 2008 to 2017, Dr. Fischer was a Senior Director of Regulatory Affairs for Pearl Therapeutics, which was sold to AstraZeneca in 2013, where she shepherded a respiratory product from the pre-IND stage to NDA approval
• Dr. Fischer has held previous positions in clinical development and regulatory affairs at GlaxoSmithKline where she played a key role in the development of market leading respiratory products, including the submission of multiple NDAs and planning/execution of several FDA Advisory Committee Meetings
• Dr. Fischer holds a Doctor of Pharmacy from University of Maryland and completed post-doctorate residency and fellowship training at University of Kentucky and at University of North Carolina/Glaxo Wellcome, respectively